Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$2.18 and last traded at C$0.21, with a volume of 49500 shares changing hands. The stock had previously closed at C$0.20.
Theralase Technologies Stock Performance
The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The company’s 50 day moving average price is C$0.19 and its 200-day moving average price is C$0.23. The company has a market cap of C$51.14 million, a PE ratio of -11.19 and a beta of 1.36.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- D-Wave Goes International With South Korea Partnership
- 3 Tickers Leading a Meme Stock Revival
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
- A Deeper Look at Bid-Ask Spreads
- 5 Small Cap Stocks With Explosive Upside Potential
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20220915161652&h=45&w=95&zc=2){kind=logo}
